Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ravindran Ankathil. (2017) ABCB1 genetic variants in leukemias: current insights into treatment outcomes. Pharmacogenomics and Personalized Medicine 10, pages 169-181.
Read now
Read now
Sonam Tulsyan, Rama Devi Mittal & Balraj Mittal. (2016) The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmacogenomics and Personalized Medicine 9, pages 47-58.
Read now
Read now
Gillian Bartlett, Jumana Antoun & Nathalie K Zgheib. (2012) Theranostics in primary care: pharmacogenomics tests and beyond. Expert Review of Molecular Diagnostics 12:8, pages 841-855.
Read now
Read now
Christopher M. Cabello, Sarah D. Lamore, Warner B. Bair$suffix/text()$suffix/text(), Angela L. Davis, Sara M. Azimian & Georg T. Wondrak. (2011) DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma. Free Radical Research 45:3, pages 276-292.
Read now
Read now
Articles from other publishers (20)
Karla Andrade de Oliveira, Surojeet Sengupta, Anil Kumar Yadav & Robert Clarke. (2023) The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. Frontiers in Endocrinology 14.
Crossref
Crossref
Ewa Totoń, Barbara Jacczak, Wojciech Barczak, Paweł Jagielski, Robert Gryczka, Hanna Hołysz, Sylwia Grodecka-Gazdecka & Błażej Rubiś. (2022) No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients—A 10-Year Follow-Up Study in the Polish Population. Genes 13:5, pages 729.
Crossref
Crossref
Soley Bayraktar, Jade Z. Zhou, Roland Bassett, Angelica M. Gutierrez Barrera, Rachel M. Layman, Vicente Valero & Banu Arun. (2020) Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. The Breast Journal 26:8, pages 1572-1582.
Crossref
Crossref
Absarul Haque, Khalid Hussain Wali Sait, Qamre Alam, Mohammad Zubair Alam, Nisreen Anfinan, Abdul Wahab Noor Wali & Mahmood Rasool. (2020) MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer. Frontiers in Genetics 11.
Crossref
Crossref
Weihua Ren, Chenxi Zhou, Yedong Liu, Keli Su, Li Jia, Luan Chen, Mo Li, Jingsong Ma, Wei Zhou, Suli Zhang, Di Zhang, Zhiliang Cong, Xuecai Niu, Shengui Zhang, Lu Shen, Cong Huai, Xiaofang Sun, Guorong Li, Shengying Qin & Liang Guo. (2019) Genetic associations of docetaxel‐based chemotherapy‐induced myelosuppression in Chinese Han population. Journal of Clinical Pharmacy and Therapeutics 45:2, pages 354-364.
Crossref
Crossref
Peng Mou, HuiJun Wang, Liping An, Qiang Yin & Juan Chang. (2018) RS7435335 located in the UGT2B7 gene may be a possible genetic marker for the clinical response and prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Journal of Cellular Biochemistry 120:5, pages 7167-7173.
Crossref
Crossref
Ahmad Aizat Abdul Aziz, Md Salzihan Md Salleh, Ibtisam Mohamad, Venkata Murali Krishna Bhavaraju, Maya Mazuwin Yahya, Andee Dzulkarnaen Zakaria, Siew Hua Gan & Ravindran Ankathil. (2018) Genotypes and haplotypes of ABCB1 contribute to TAC chemotherapy response in Malaysian triple negative breast cancer patients. Meta Gene 16, pages 21-27.
Crossref
Crossref
Robert Gharavi & Hazem E. Hassan. 2018. Genomics-Driven Healthcare. Genomics-Driven Healthcare
133
175
.
Virginia Bosó, María José Herrero, Ana Santaballa, Laura Palomar, Juan E Megias, Helena de la Cueva, Luis Rojas, María Remedios Marqués, José Luis Poveda, Joaquin Montalar & Salvador F Aliño. (2014) SNPs and taxane toxicity in breast cancer patients. Pharmacogenomics 15:15, pages 1845-1858.
Crossref
Crossref
S J An, Y S Huang, Z H Chen, J F Han, J J Yang, Q Zhou, Z Xie, Y Yang, H H Yan & Y L Wu. (2014) Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy. Cancer Gene Therapy 21:3, pages 110-114.
Crossref
Crossref
Tristan M. Sissung, Andrew K. L. Goey, Ariel M. Ley, Jonathan D. Strope & William D. Figg. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
91
120
.
Zainab AwadaSyed HaiderArafat TfayliAli BazarbachiNagi S. El-SaghirZiad SalemAli ShamseddineAli TaherNathalie Khoueiry Zgheib. (2013) Pharmacogenomics Variation in Drug Metabolizing Enzymes and Transporters in Relation to Docetaxel Toxicity in Lebanese Breast Cancer Patients: Paving the Way for OMICs in Low and Middle Income Countries. OMICS: A Journal of Integrative Biology 17:7, pages 353-367.
Crossref
Crossref
Nalini Raghavachari & Marjan Gucek. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine
3
18
.
Birgit Regenfu, Felix Bock & Claus Cursiefen. (2012) Corneal angiogenesis and lymphangiogenesis. Current Opinion in Allergy & Clinical Immunology 12:5, pages 548-554.
Crossref
Crossref
Leonor Munoz Alcivar & Yashwant Pathak. 2012. Antibody-Mediated Drug Delivery Systems. Antibody-Mediated Drug Delivery Systems
35
55
.
Christine L. H. Snozek. 2012. Pharmacogenomics in Clinical Therapeutics. Pharmacogenomics in Clinical Therapeutics
39
52
.
Evy Cleeren, Johan Van der Heyden, Angela Brand & Herman Van Oyen. (2011) Public health in the genomic era: will Public Health Genomics contribute to major changes in the prevention of common diseases?. Archives of Public Health 69:1.
Crossref
Crossref
Sumit Parmar, Julia Carolin Stingl, Ariana Huber-Wechselberger, Alexander Kainz, Wilfried Renner, Uwe Langsenlehner, Peter Krippl, Jürgen Brockmöller & Elisabeth Haschke-Becher. (2011) Impact of UGT2B7
His268Tyr
polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Research 13:3.
Crossref
Crossref
Asako YamayoshiMariko YasuharaSanjeev GalandeAkio KoboriAkira Murakami. (2011) Decoy-DNA Against Special AT-Rich Sequence Binding Protein 1 Inhibits the Growth and Invasive Ability of Human Breast Cancer. Oligonucleotides 21:2, pages 115-121.
Crossref
Crossref
Pelagia G. Tsoutsou, Yazid Belkacemi, Joseph Gligorov, Abraham Kuten, Hamouda Boussen, Nuran Bese & Michael I. Koukourakis. (2010) Optimal Sequence of Implied Modalities in the Adjuvant Setting of Breast Cancer Treatment: An Update on Issues To Consider. The Oncologist 15:11, pages 1169-1178.
Crossref
Crossref